Page 138 - Binder2

But in the platform model, the real differentiator is how
long the therapy lasts.

Durability becomes the metric that defines success:

• How long before the immune system pushes back?
• How long before the patient needs to switch?
• How long before trust erodes?

Biologics that stay effective longer don’t just outperform
competitors—they collapse cost curves, improve
adherence, and build brand credibility over time.

Operationally, This Means Thinking in
Systems—Not Cycles

Right now, each biologic is often developed with a single
use case in mind—an asset built to capture one indication,
then retrofitted for expansion.

In a platform approach, that logic flips. You build the core
immune-compatible foundation first, then apply it
broadly:

Traditional
Feature Platform Approach
Model
Single use- Core immune-compatible
Initial Design
case platform
Expansion Retrofitted Built-in flexibility
Strategy

136